Cargando…

O-GlcNAcylation: An Emerging Protein Modification Regulating the Hippo Pathway

SIMPLE SUMMARY: The contact point between the Hippo pathway, which serves as a central hub for various external environments, and O-GlcNAcylation, which is a non-canonical glycosylation process acting as a dynamic regulator in various signal transduction pathways, has recently been identified. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Eunah, Kang, Jeong Gu, Jho, Eek-hoon, Yang, Won Ho, Cho, Jin Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221189/
https://www.ncbi.nlm.nih.gov/pubmed/35740678
http://dx.doi.org/10.3390/cancers14123013
_version_ 1784732559450570752
author Kim, Eunah
Kang, Jeong Gu
Jho, Eek-hoon
Yang, Won Ho
Cho, Jin Won
author_facet Kim, Eunah
Kang, Jeong Gu
Jho, Eek-hoon
Yang, Won Ho
Cho, Jin Won
author_sort Kim, Eunah
collection PubMed
description SIMPLE SUMMARY: The contact point between the Hippo pathway, which serves as a central hub for various external environments, and O-GlcNAcylation, which is a non-canonical glycosylation process acting as a dynamic regulator in various signal transduction pathways, has recently been identified. This review aims to summarize the function of O-GlcNAcylation as an intrinsic and extrinsic regulator of the Hippo pathway. ABSTRACT: The balance between cellular proliferation and apoptosis and the regulation of cell differentiation must be established to maintain tissue homeostasis. These cellular responses involve the kinase cascade-mediated Hippo pathway as a crucial regulator. Hence, Hippo pathway dysregulation is implicated in diverse diseases, including cancer. O-GlcNAcylation is a non-canonical glycosylation that affects multiple signaling pathways through its interplay with phosphorylation in the nucleus and cytoplasm. An abnormal increase in the O-GlcNAcylation levels in various cancer cells is a potent factor in Hippo pathway dysregulation. Intriguingly, Hippo pathway dysregulation also disrupts O-GlcNAc homeostasis, leading to a persistent elevation of O-GlcNAcylation levels, which is potentially pathogenic in several diseases. Therefore, O-GlcNAcylation is gaining attention as a protein modification that regulates the Hippo pathway. This review presents a framework on how O-GlcNAcylation regulates the Hippo pathway and forms a self-perpetuating cycle with it. The pathological significance of this self-perpetuating cycle and clinical strategies for targeting O-GlcNAcylation that causes Hippo pathway dysregulation are also discussed.
format Online
Article
Text
id pubmed-9221189
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92211892022-06-24 O-GlcNAcylation: An Emerging Protein Modification Regulating the Hippo Pathway Kim, Eunah Kang, Jeong Gu Jho, Eek-hoon Yang, Won Ho Cho, Jin Won Cancers (Basel) Review SIMPLE SUMMARY: The contact point between the Hippo pathway, which serves as a central hub for various external environments, and O-GlcNAcylation, which is a non-canonical glycosylation process acting as a dynamic regulator in various signal transduction pathways, has recently been identified. This review aims to summarize the function of O-GlcNAcylation as an intrinsic and extrinsic regulator of the Hippo pathway. ABSTRACT: The balance between cellular proliferation and apoptosis and the regulation of cell differentiation must be established to maintain tissue homeostasis. These cellular responses involve the kinase cascade-mediated Hippo pathway as a crucial regulator. Hence, Hippo pathway dysregulation is implicated in diverse diseases, including cancer. O-GlcNAcylation is a non-canonical glycosylation that affects multiple signaling pathways through its interplay with phosphorylation in the nucleus and cytoplasm. An abnormal increase in the O-GlcNAcylation levels in various cancer cells is a potent factor in Hippo pathway dysregulation. Intriguingly, Hippo pathway dysregulation also disrupts O-GlcNAc homeostasis, leading to a persistent elevation of O-GlcNAcylation levels, which is potentially pathogenic in several diseases. Therefore, O-GlcNAcylation is gaining attention as a protein modification that regulates the Hippo pathway. This review presents a framework on how O-GlcNAcylation regulates the Hippo pathway and forms a self-perpetuating cycle with it. The pathological significance of this self-perpetuating cycle and clinical strategies for targeting O-GlcNAcylation that causes Hippo pathway dysregulation are also discussed. MDPI 2022-06-18 /pmc/articles/PMC9221189/ /pubmed/35740678 http://dx.doi.org/10.3390/cancers14123013 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kim, Eunah
Kang, Jeong Gu
Jho, Eek-hoon
Yang, Won Ho
Cho, Jin Won
O-GlcNAcylation: An Emerging Protein Modification Regulating the Hippo Pathway
title O-GlcNAcylation: An Emerging Protein Modification Regulating the Hippo Pathway
title_full O-GlcNAcylation: An Emerging Protein Modification Regulating the Hippo Pathway
title_fullStr O-GlcNAcylation: An Emerging Protein Modification Regulating the Hippo Pathway
title_full_unstemmed O-GlcNAcylation: An Emerging Protein Modification Regulating the Hippo Pathway
title_short O-GlcNAcylation: An Emerging Protein Modification Regulating the Hippo Pathway
title_sort o-glcnacylation: an emerging protein modification regulating the hippo pathway
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221189/
https://www.ncbi.nlm.nih.gov/pubmed/35740678
http://dx.doi.org/10.3390/cancers14123013
work_keys_str_mv AT kimeunah oglcnacylationanemergingproteinmodificationregulatingthehippopathway
AT kangjeonggu oglcnacylationanemergingproteinmodificationregulatingthehippopathway
AT jhoeekhoon oglcnacylationanemergingproteinmodificationregulatingthehippopathway
AT yangwonho oglcnacylationanemergingproteinmodificationregulatingthehippopathway
AT chojinwon oglcnacylationanemergingproteinmodificationregulatingthehippopathway